Arcturus partners with Thermo Fisher to support Phase 3 development and potential commercialization of ARCT-032 for cystic fibrosis.
Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) is collaborating with Thermo Fisher Scientific Inc. (NYSE:TMO) to support the Phase 3 development and potential commercialization of ARCT-032, the company’s investigational messenger RNA therapy for cystic fibrosis.
Read Next
Earnings
Thermo Fisher Flags 'Modest Inflation' Risk Amid Middle East Tensions
Thermo Fisher beats Q1 estimates, lifts FY26 outlook as bioproduction drives growth amid macro pressures and mixed segment performance.
Arcturus Therapeutics Announces Strategic Collaboration with Thermo Fisher Scientific to Advance ARCT-032 for Cystic Fibrosis
Faron Pharmaceuticals Ltd: Grant of Options
United Therapeutics Corporation Acquires Thymmune Therapeutics
Arima Genomics Announces Distribution Partnership with Active Motif for Research-Specific Hi-C Sequencing Kits and Services
Zymeworks acquires struggling Theravance for $929M
Altasciences supporta la tappa fondamentale di sviluppo per il candidato terapeutico principale di Steel Therapeutics, Fizurex™
Arcturus Therapeutics Announces Strategic Collaboration with Thermo Fisher Scientific to Advance ARCT-032 for Cystic Fibrosis
Thermo Fisher Scientific Announces Quarterly Dividend
Deal would mark latest move by a life sciences group to jettison lower-growth assets
TURKU, FI / ACCESS Newswire / July 1, 2026 / Faron Pharmaceuticals Ltd. (HEL:FARON)(LSE:FARN), a clinical-stage biopharmaceutical…
United Therapeutics (UTHR) acquires Thymmune Therapeutics for $140M upfront, with up to $160M in milestone-based payments.
Expanding platform with next-generation VHH, lambda common light chain, and specialized long-CDR3 technologies MOUNTAIN VIEW, CA…
